期刊
NATURE REVIEWS DRUG DISCOVERY
卷 18, 期 10, 页码 770-796出版社
NATURE PORTFOLIO
DOI: 10.1038/s41573-019-0033-4
关键词
-
资金
- British Heart Foundation [BHF/TARGETPDE/PG/17/26/32881]
- Medical Research Council [MC-PC-13063, MC-PC-15039]
- [1R01MH101130]
- [1R01AG061200]
- MRC [MR/N003403/1, MC_PC_15039, MC_PC_13063] Funding Source: UKRI
Phosphodiesterases (PDEs), enzymes that degrade 3',5'-cyclic nucleotides, are being pursued as therapeutic targets for several diseases, including those affecting the nervous system, the cardiovascular system, fertility, immunity, cancer and metabolism. Clinical development programmes have focused exclusively on catalytic inhibition, which continues to be a strong focus of ongoing drug discovery efforts. However, emerging evidence supports novel strategies to therapeutically target PDE function, including enhancing catalytic activity, normalizing altered compartmentalization and modulating post-translational modifications, as well as the potential use of PDEs as disease biomarkers. Importantly, a more refined appreciation of the intramolecular mechanisms regulating PDE function and trafficking is emerging, making these pioneering drug discovery efforts tractable.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据